



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

| APPLICATION NO.   | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|-------------|----------------------|---------------------|------------------|
| 10/800,077  | 03/12/2004  | Ramachandra Reddy    | VASG-P01-001        | 2078             |
| 28120   | 7590        | 04/03/2006           | EXAMINER            |                  |
| FISH & NEAVE IP GROUP<br>ROPES & GRAY LLP<br>ONE INTERNATIONAL PLACE<br>BOSTON, MA 02110-2624 |             |                      | CHONG, KIMBERLY     |                  |
|   |             |                      | ART UNIT            | PAPER NUMBER     |
|   |             |                      | 1635                |                  |
| DATE MAILED: 04/03/2006   |             |                      |                     |                  |

Please find below and/or attached an Office communication concerning this application or proceeding.

|                              |                               |                              |  |
|------------------------------|-------------------------------|------------------------------|--|
| <b>Office Action Summary</b> | Application No.<br>10/800,077 | Applicant(s)<br>REDDY ET AL. |  |
|                              | Examiner<br>Kimberly Chong    | Art Unit<br>1635             |  |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 23 January 2006.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1-91 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-13, 26-29, 59 and 60 is/are rejected.
- 7) ☒ Claim(s) 14-17 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 12 March 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>3/14/05, 12/6/04</u> . | 6) <input checked="" type="checkbox"/> Other: <u>sequence alignment</u> .               |

## **DETAILED ACTION**

### ***Election/Restrictions***

Applicant's election with traverse of Group I, claims 1-29 and 59-60, in the reply filed on 09/12/05 is acknowledged. Applicants were required to further elect a nucleic acid inhibitor of EphB4 in the restriction requirement filed 10/21/2005. The restriction required applicants to elect a nucleic acid inhibitor of EphB4 selected from Table 7. Applicants point out that examiner erred in not requiring applicants to elect a nucleic acid inhibitor from Table 6 or Table 7. Applicant's election of an antisense nucleic acid inhibitor of EphB4 from Table 6 is acknowledged in the reply filed 1/23/2006. During a telephone conversation with Angela Guo on 03/21/2006, applicant confirmed the election of antisense sequence having SEQ ID NO: 231 as the nucleic acid inhibitor. Therefore, claims 18-25 and sequences in Table 7 drawn to RNAi nucleic acid inhibitors are withdrawn from further consideration as being drawn to a non-elected invention.

Applicants traverse the requirement to elect a single sequence because there is no search burden to search and examine all the claimed inhibitors of EphB4 since all the nucleic acid sequences share the same generic feature "i.e. comprising at least a portion that hybridizes to an EphB4 transcript under physiological conditions and decreases expression of EphB4 in a cell." Applicants argue a search using generic claim terms would encompass a broad search that can adequately cover the claimed subject matter.

A search for the claimed nucleic acid sequences requires more than a text search for claim terms and as stated in the restriction requirement filed 10/21/2006, a

Art Unit: 1635

search of more than one (1) of the nucleic acid sequences claimed presents an undue burden on the Patent and Trademark Office due to the complex nature of the search and corresponding examination of more than one (1) of the claimed nucleic acid sequences. Further, a search for one of the claimed nucleic acid sequences will not necessarily reveal art for any other claimed nucleic acid sequences. Therefore, the requirement is still deemed proper and is therefore made FINAL.

### ***Claim Objections***

Claims 14-17 are objected to as being dependent upon a rejected base claim and reciting non-elected subject matter, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims and deleting non-elected subject matter.

### ***Status of the Application***

Claims 1-91 are pending. Claims 1-17, 26-29 and 59-60 are currently under examination. Claims 18-25 are withdrawn as being drawn to a non-elected invention.

### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 29 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which

Art Unit: 1635

was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claim 29 is drawn to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 transcript wherein the nucleic acid compound inhibits EphB4 expression in cells by 50% or greater when contacted with the cells under physiological conditions at a concentration of 5 micromolar.

The specification as filed discloses antisense compounds targeted to EphB4 that inhibit expression as designated by a series of "+" symbols (see Table 8).

The specification does not provide adequate written description of a nucleic acid compound targeted to a nucleic acid encoding EphB4 that inhibits expression of EphB4 by 50% or greater. Therefore, in only disclosing a limited number of nucleic acid compounds targeting EphB4 with various ranges of inhibition, the specification does not provide information on what nucleic acid compound is capable of inhibiting any EphB4 mRNA expression by 50% or greater.

The specification does not provide specific guidance that would allow the skilled artisan to recognize that Applicant was in possession of the instant invention, commensurate in scope with what is now claimed: a nucleic acid compound complementary to a nucleic acid encoding EphB4 that inhibits EphB4 mRNA by 50% or greater. For example, what antisense structure or sequence would one skilled in the art know or expect would inhibit EphB4 mRNA expression 50% or greater, based on the specification as filed. Further, it is not clear from Table 7 what percentage inhibition the

Art Unit: 1635

antisense sense sequences have in cells because the inhibition is listed as "+" with no designation of what the "+" symbols are equivalent to in relation to percent inhibition.

Additionally, there are no examples provided in the specification nor does the prior art provide a core structure or motif that would impart the function of inhibiting by at 50%. Therefore, one is left to empirically screen for antisense compounds of the invention.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession *of the invention*. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed*." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116.)

MPEP 2163 states in part, "An adequate written description of a chemical invention also requires a precise definition, such as by structure, formula, chemical name, or physical properties, and not merely a wish or plan for obtaining the chemical invention claimed. See, e.g., *Univ. of Rochester v. G.D. Searle & Co.*, 358 F.3d 916, 927, 69 USPQ2d 1886, 1894-95 (Fed. Cir. 2004) (The patent at issue claimed a method of selectively inhibiting PGHS-2 activity by administering a non-steroidal compound that selectively inhibits activity of the PGHS-2 gene product, however the patent did not disclose any compounds that can be used in the claimed methods. While there was a description of assays for screening compounds to identify those that inhibit the expression or activity of the PGHS-2 gene product, there was no disclosure of which

Art Unit: 1635

peptides, polynucleotides, and small organic molecules selectively inhibit PGHS-2. The court held that "[w]ithout such disclosure, the claimed methods cannot be said to have been described.").

Thus, the instantly claimed invention cannot be said to have been adequately described in a way that would convey with reasonable clarity to those skilled in the art that, as of the filing date sought, applicant was in possession of the claimed invention

***Claim Rejections - 35 USC § 102 or 35 USC § 103***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-7, 9-13 and 59-60 are rejected under 35 U.S.C. 102(b) or 35 U.S.C. 103(a) as being anticipated by or obvious over Bennett *et al.* (Patent No: 6,150,162).

The claims are drawn to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 transcript, wherein the EphB4 transcript has a nucleotide sequence set forth in SEQ ID NO: 392, wherein the nucleic acid compound comprises a nucleotide sequence that is complementary to a region consisting of not more than 500 nucleotides of SEQ ID NO: 392, wherein the region has at least 8 contiguous nucleotides of the SEQ ID NO: 392, wherein the nucleic acid compound is from 14 to 50 nucleotides in length, wherein the compound is single-stranded, a DNA molecule, a RNA molecule or DNA strand and an RNA strand modified or is an antisense nucleic acid, wherein the compound comprises one modified backbone or base moieties, wherein the compound has at least one internucleotide linkage, wherein the compound comprises at least one 2'-O-alkylated ribonucleotide, wherein the nucleic acid compound inhibits EphB4 expression in cells by 50% or greater and drawn to pharmaceutical composition comprising said nucleic acid compound.

Bennett *et al.* teach a compound, 18 nucleobases in length (see attached sequence alignment and SEQ ID NO: 82). Bennett *et al.* teach the compound is single-stranded, a DNA molecule or a RNA molecule (see column 5, lines 44-60), or DNA strand and an RNA strand modified or is an antisense nucleic acid (see column 9, lines 59-68), wherein the compound comprises one modified backbone or base moieties, wherein the compound has at least one internucleotide linkage, wherein the compound comprises at least one 2'-O-alkylated ribonucleotide (see columns 7-8). Bennett *et al.* teach pharmaceutical compositions comprising said nucleic acid compounds (see column 11). Therefore, the nucleic acid sequence taught by Bennett *et al.* meets the



Art Unit: 1635

structural limitation of claims 1-7, 9-13 and 59-60 of the instant application and would be expected to hybridize to a nucleic acid encoding of EphB4. See, for example, MPEP 2112, which states “[w]here applicant claims a composition in terms of a function, property or characteristic and the composition of the prior art is the same as that of the claim but the function is not explicitly disclosed by the reference, the examiner may make a rejection under both 35 U.S.C. 102 and 103, expressed as a 102/103 rejection. “There is nothing inconsistent in concurrent rejections for obviousness under 35 U.S.C. 103 and for anticipation under 35 U.S.C. 102.” *In re Best*, 562 F.2d 1252, 1255 n.4, 195 USPQ 430, 433 n.4 (CCPA 1977). This same rationale should also apply to product, apparatus, and process claims claimed in terms of function, property or characteristic. Therefore, a 35 U.S.C. 102/103 rejection is appropriate for these types of claims as well as for composition claims.

Thus, the instant claims are anticipated or is obvious over Bennett *et al.*

Claims 1-13, 26-29 and 59-60 are rejected under 35 U.S.C. 102(b) or 35 U.S.C. 103(a) as being anticipated by or obvious over Pavco *et al.* (Patent No: 6,346,398).

The claims are drawn to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 transcript, wherein the EphB4 transcript has a nucleotide sequence set forth in SEQ ID NO: 392, wherein the nucleic acid compound comprises a nucleotide sequence that is complementary to a region consisting of n more than 500 nucleotides of SEQ Id NO: 392, wherein the region has at least 8

Art Unit: 1635

contiguous nucleotides of the SEQ ID NO: 392, wherein the nucleic acid compound is from 14 to 50 nucleotides in length, wherein the compound is single-stranded, double-stranded, a DNA molecule, a RNA molecule or DNA strand and an RNA strand modified or is an antisense nucleic acid, wherein the compound comprises one modified backbone or base moieties, wherein the compound has at least one internucleotide linkage, wherein the compound comprises at least one 2'-O-alkylated ribonucleotide, wherein the compound is an enzymatic nucleic acid, wherein the enzymatic compound is a ribozyme, wherein the enzymatic nucleic acid is a DNA enzyme, wherein the nucleic acid compound inhibits EphB4 expression in cells by 50% or greater and drawn to pharmaceutical composition comprising said nucleic acid compound.

Pavco *et al.* teach a compound, 17 nucleobases in length (see attached sequence alignment and SEQ ID NO: 2794). Pavco *et al.* teach the compound is single-stranded, double-stranded, a DNA molecule or a RNA molecule or DNA strand and an RNA strand modified or an antisense nucleic acid (see column 4 and 5, lines 1-30 and 5-10 respectively), wherein the compound comprises one modified backbone or base moieties, wherein the compound has at least one internucleotide linkage, wherein the compound comprises at least one 2'-O-alkylated ribonucleotide (see Figures 14-18). Pavco *et al.* teach pharmaceutical compositions comprising said nucleic acid compounds (see column 22 lines 1-40). Therefore, the nucleic acid sequence taught by Pavco *et al.* meets the structural limitation of claims 1-13, 26-29 and 59-60 of the instant application and would be expected to hybridize to a nucleic acid encoding of EphB4. See, for example, MPEP 2112, which states "[w]here applicant claims a composition in

Art Unit: 1635

terms of a function, property or characteristic and the composition of the prior art is the same as that of the claim but the function is not explicitly disclosed by the reference, the examiner may make a rejection under both 35 U.S.C. 102 and 103, expressed as a 102/103 rejection. "There is nothing inconsistent in concurrent rejections for obviousness under 35 U.S.C. 103 and for anticipation under 35 U.S.C. 102." *In re Best*, 562 F.2d 1252, 1255 n.4, 195 USPQ 430, 433 n.4 (CCPA 1977). This same rationale should also apply to product, apparatus, and process claims claimed in terms of function, property or characteristic. Therefore, a 35 U.S.C. 102/103 rejection is appropriate for these types of claims as well as for composition claims.

Thus, the instant claims are anticipated or is obvious over Pavco *et al.*

### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kimberly Chong whose telephone number is 571-272-3111. The examiner can normally be reached Monday thru Friday between 7-4 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached at 571-272-0811. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file

Art Unit: 1635

folder(s) as well as general patent information available to the public. For more information about the PAIR system, see <http://pair-direct.uspto.gov>.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Kimberly Chong  
Examiner  
Art Unit 1635

A handwritten signature in black ink, appearing to read 'Andrew Wang', with a stylized, looping flourish at the end.

**ANDREW WANG**  
**SUPERVISORY PATENT EXAMINER**  
**TECHNOLOGY CENTER 1600**

US-09-199-859-46  
; Sequence 46, Application US/09199859  
; Patent No. 6063008  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Brett P. Monia  
; TITLE OF INVENTION: ANTISENSE MODULATION OF NF-KAPPA-B P65 SUBUNIT EXPRESSION  
; FILE REFERENCE: RTS-0025  
; CURRENT APPLICATION NUMBER: US/09/199, 859  
; CURRENT FILING DATE: 1998-11-25  
; NUMBER OF SEQ ID NOS: 47  
; SEQ ID NO 46  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-09-199-859-46

Query Match 0.3%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 52;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2669 TGGAGGAGAACTCTTC 2684  
DB 2 TGGAGGAGAACTCTTC 17

RESULT 53  
US-09-213-719-82/c  
; Sequence 82, Application US/09213719B  
; Patent No. 6150162  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Lex M. Cowsett  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD44 EXPRESSION  
; FILE REFERENCE: RTS-0006  
; CURRENT APPLICATION NUMBER: US/09/213, 719B  
; CURRENT FILING DATE: 1998-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 82  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-09-213-719-82

Query Match 0.3%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 52;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2702 GCTCCCTGGGAGGAAA 2717  
DB 16 GCTCCCTGGGAGGAAA 1

RESULT 54  
US-09-044-602-2  
; Sequence 2, Application US/09044602  
; Patent No. 6613750  
; GENERAL INFORMATION:  
; APPLICANT: Depinho, Robert A.  
; TITLE OF INVENTION: A METHOD OF INHIBITING CELL PROLIFERATION USING AN ANTI-ONCOGENE  
; FILE REFERENCE: 96700/469  
; CURRENT APPLICATION NUMBER: US/09/044, 602  
; CURRENT FILING DATE: 1998-03-19  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 2  
; LENGTH: 18  
; TYPE: DNA

; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: primer for MDN2 mutant  
US-09-044-602-2

Query Match 0.3%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 52;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3598 GAAGTCCCAACATCT 3613  
DB 2 GAAGTCCCAACATCT 17

RESULT 55  
US-09-856-747-46  
; Sequence 46, Application US/09856747  
; Patent No. 6656688  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Brett P. Monia  
; APPLICANT: Lex M. Cowsett  
; APPLICANT: ISIS PHARMACEUTICALS, INC.  
; TITLE OF INVENTION: ANTISENSE MODULATION OF NF-KAPPA-B P65 SUBUNIT EXPRESSION  
; FILE REFERENCE: RTSP-0116  
; CURRENT APPLICATION NUMBER: US/09/856, 747  
; CURRENT FILING DATE: 2001-05-24  
; PRIOR APPLICATION NUMBER: US 09/199, 859  
; PRIOR FILING DATE: 1998-11-25  
; NUMBER OF SEQ ID NOS: 47  
; SEQ ID NO 46  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-09-856-747-46

Query Match 0.3%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 52;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2669 TGGAGGAGAACTCTTC 2684  
DB 2 TGGAGGAGAACTCTTC 17

RESULT 56  
US-10-424-630-2  
; Sequence 2, Application US/10424630  
; Patent No. 6897197  
; GENERAL INFORMATION:  
; APPLICANT: Depinho, Robert A.  
; TITLE OF INVENTION: A METHOD OF INHIBITING CELL PROLIFERATION USING AN ANTI-ONCOGENE  
; FILE REFERENCE: 96700/469  
; CURRENT APPLICATION NUMBER: US/10/424, 630  
; CURRENT FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: US/09/044, 602  
; PRIOR FILING DATE: 1998-03-19  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 2  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: primer for MDN2 mutant  
US-10-424-630-2

Query Match 0.3%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 52;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Suite 4700  
STATE: Los Angeles  
CITY: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq for Windows 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/985,162  
FILING DATE: 04 December 1997  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/036,476  
FILING DATE: 31 January 1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 230/107  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 326:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear

US-08-985-162-326

Query Match 0.3%; Score 13.8; DB 1;  
Best Local Similarity 64.7%; Pred. No. 59;  
Matches 11; Conservative 4; Mismatches 2;

QY 2776 AGTGATGCTCGAGTTA 2792  
||:|:|:|:|:|:|:  
DB 1 AGGAGUGUCUGAGGCUA 17

RESULT 74  
US-07-974-409C-96  
; Sequence 96, Application US/07974409C  
; Patent No. 6300058  
; GENERAL INFORMATION:  
; APPLICANT: Akitaya, Tateuo  
; APPLICANT: Mitsuhashi, Masato  
; APPLICANT: Cooper, Allan  
; TITLE OF INVENTION: METHOD AND REAGENT  
; TITLE OF INVENTION: FOR MEASURING MESSENGER RNA  
; NUMBER OF SEQUENCES: 457  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Knobbe, Martens, Olson, and Bear  
; STREET: 620 Newport Center Dr. Sixteenth Floor  
; CITY: Newport Beach  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 92660  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/974,409C  
; FILING DATE: 12-NOV-1992  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:

NAME: Altman, Daniel E.  
REGISTRATION NUMBER: 34,115  
REFERENCE/DOCKET NUMBER: HITACHI.006CP2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 714-760-0404  
TELEFAX: 714-760-9502  
INFORMATION FOR SEQ ID NO: 96:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA to mRNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
US-07-974-409C-96

Query Match 0.3%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 59;  
Matches 15; Conservative 0; Mismatches 2; Indels

QY 149 CCAGTCCGACGAGCCTC 165  
||||||| |||||  
Db 1 CCAGTCCGACATGCTC 17

RESULT 75  
US-08-584-040-2794/c  
Sequence 2794, Application US/08584040  
Patent No. 6346398  
GENERAL INFORMATION:  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
TITLE OF INVENTION: TREATMENT OF DISEASES OR  
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
TITLE OF INVENTION: GROWTH FACTOR  
NUMBER OF SEQUENCES: 8502  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/584,040  
FILING DATE: January 11, 1996  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/005,974  
FILING DATE: October 26, 1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/064  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 2794:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs